中國碳中和(01372.HK)中期收益2.31億港元 同比增長5.67%
格隆匯8月30日丨中國碳中和(01372.HK)發佈公吿,截至2022年6月30日止六個月,公司收益2.31億港元,同比增長5.67%;公司擁有人應占溢利391.6萬港元,每股盈利1.3港仙。
集團自2021年初發展全球碳中和業務,以碳中和相關領域的碳信用資產開發、經營管理及投資以及碳諮詢和碳中和規劃為核心,創立了獨特的市場定位,並且通過積極部署負碳排放等基礎產業,實現新型資產開發與經營管理與產業結合的獨特的碳中和協同發展的方式,創造可持續和高收益的業務模式。
自2021年初,集團開始拓展全球碳中和業務,並持續發展良好,此業務於2022年上半年繼續錄得良好的業績回報。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.